14. Segment Data

The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company’s reportable segments sales and net income consisted of:


	Year Ended
	December 31,
	2019		2018
Revenue from external customers
Human Health	$	5,673,068	$	4,121,913
Animal Health		102,189		294,232
Consolidated Totals	$	5,775,257	$	4,416,145

Segment net loss
Human Health	$	(19,263,550)	$	(12,337,529)
Animal Health		(19,275,886)		(19,808,528)
Consolidated Totals	$	(38,539,436)	$	(32,146,057)

The Company’s reportable segments assets consisted of the following:


	December 31,		December 31,
	2019		2018
Segment assets
Human Health	$	32,431,891	$	37,985,935
Animal Health		68,169,193		54,893,593
Total	$	100,601,084	$	92,879,528

The reconciliation of segments assets to the consolidated assets is as follows:


	December 31,		December 31,
	2019		2018
Total assets for reportable segments	$	100,601,084	$	92,879,528
Less: Investment in subsidiary		(29,240,965)		(29,240,965)
Less: Intercompany loan		(34,949,698)		(22,596,618)
Consolidated Totals	$	36,410,421	$	41,041,945